Publications

5677 Results

A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Authors
N Mehta-Shah;N Bartlett;S Barta;J Amengual;S Horwitz;B Kahl;J Friedberg;T Dockter;S Geyer;J Leonard
Journal / Conference
ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051902

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC)

Authors
H Arai;Y Yang;J Millstein;Y Denda;F-S Ou;F Innocenti;H Takeda;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;N Kawanishi;P Jayachandran;S Soni;W Zhang;A Venook;Y Sunakawa;H-J Lenz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3586), poster 380; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance)

Authors
C Kohn;F-S Ou;C Ma;N Larson;T Zemla;C Yuan;D Niedzwiecki;B Hollis;A Nixon;H-J Lenz;CD Blanke;R Goldberg;R Mayer;A Venook;E O'Reilly;J Meyerhardt;K Ng
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3553), poster 347; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405

Authors
W Zhang;F Battaglin;Y Yang;F-S Ou;F Innocenti;H Arai;S Soni;P Jayachandran;M Bertagnolli;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;CD Blanke;A Venook;O Kabbarah;J Millstein;H-J Lenz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3580), poster 374; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

E1Q11: Engendering Reproductive health in Oncologic Survivorship (EROS)

Authors
A Patel;J-W Lee;H Zaren;E Radeke;R Lerner;J Fukui;D Makower;D Tamkus;K Rosland;W Adler;A Throckmorton;S Ghamande;D Cella;MJ Fisch;L Wagner
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 1519), poster 113; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Cancer Survivorship

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142

Authors
J Eads;P Catalano;G Fisher;D Rubin;A Iagaru;D Klimstra;B Konda;M Kwong;J Chan;A De Jesus-Acosta;T Halfdanarson;W Shaib;H Soares;S Hong;T Wong;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 4020), poster #8; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2142

SWOG S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide (P/E) with or without Atezolizumab (NSC#783608) in Patients (pts) with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Authors
D Zhen;E Mayerson;E Chiorean;E Burgess;E Swisher;C Gay;L Byers;I Wistuba;H Mahdi;S Das;J Starr;M Othus;YK Chae;R Kurzrock
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4179), poster 155a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S2012

EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors

Authors
K Ciombor;S Hong;C Eng;X Yao;M Thet Cho;YN You;P Das;A Chakravarthy;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3644), poster 430A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2201

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy vs targeted therapy in patients (pts) with BRAF mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)

Authors
R Jensen;Y Zheng;M Atkins;B Chmielowski;A Tarhini;T-G Truong;D Divar;M O'Rourke;B Curti;J Brell;K Kendra;A Ikeguchi;S Lee;A Potosky;J Wolchok
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9559), poster 152; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
CTSU/EA6134

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop): ECOG-ACRIN EA6192.

Authors
G Gibney;S Lee;M Atkins;T Wong;J Guerriero;T Marron;G Cohen;T-G Truong;R Carvajal;B Snyder;M Farwell;J Kirkwood;J Wolchok
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9591), poster 183A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
EA6192